Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker KZIA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Dauntless Investment Group, LLC | 842,340 | 5.4% | SCHEDULE 13G/A ↗ |
| Aug 19, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Chernett Jorey | 2.34M | 19.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Neil Shahrestani | 575,778 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Ikarian Capital, LLC | 575,778 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Lynwood Opportunities Master Fund | 264.98M | 4.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Ben Shapiro | 264.98M | 4.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Lynwood Capital Management Inc. | 264.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 27, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Chernett Jorey | 2.11M | 18.5% | SCHEDULE 13G/A ↗ |
| Mar 31, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Chernett Jorey | 1.59M | 13.9% | SCHEDULE 13G/A ↗ |
| Mar 30, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Ashkan Mapar | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Mar 30, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Alumni Capital GP LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Mar 30, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Alumni Capital LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 20, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Chernett Jorey | 1.41M | 12.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Neil Shahrestani | 580,754 | 5.1% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Ikarian Capital, LLC | 580,754 | 5.1% | SCHEDULE 13G ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Dauntless Investment Group, LLC | 1 | 0.0% | SCHEDULE 13G/A ↗ |
| Jan 23, 2026 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Lynwood Opportunities Master Fund | 308.00M | 5.4% | SCHEDULE 13G ↗ |
| Jan 23, 2026 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Ben Shapiro | 308.00M | 5.4% | SCHEDULE 13G ↗ |
| Jan 23, 2026 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Lynwood Capital Management Inc. | 308.00M | 5.4% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Dauntless Investment Group, LLC | 176,822 | 9.9% | SCHEDULE 13G/A ↗ |
| Sep 12, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Ashkan Mapar | 178,591 | 10.0% | SCHEDULE 13G/A ↗ |
| Sep 12, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Alumni Capital GP LLC | 178,591 | 10.0% | SCHEDULE 13G/A ↗ |
| Sep 12, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Alumni Capital LP | 178,591 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 5, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Dauntless Investment Group, LLC | 115,769 | 8.4% | SCHEDULE 13G/A ↗ |
| Jun 13, 2025 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Dauntless Investment Group, LLC | 80,617 | 5.9% | SCHEDULE 13G ↗ |
| Jun 12, 2025 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Chernett Jorey | 137,200 | 9.9% | SCHEDULE 13G ↗ |
| Mar 19, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Ashkan Mapar | 773,494 | 10.0% | SCHEDULE 13G/A ↗ |
| Mar 19, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Alumni Capital GP LLC | 773,494 | 10.0% | SCHEDULE 13G/A ↗ |
| Mar 19, 2025 | SCHEDULE 13G/A (amended) | KZIA Kazia Therapeutics Limited | Alumni Capital LP | 773,494 | 10.0% | SCHEDULE 13G/A ↗ |
| Jan 16, 2025 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Ashkan Mapar (1) [xx-xxxxxxx] | 558,918 | 10.0% | SCHEDULE 13G ↗ |
| Jan 16, 2025 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Alumni Capital GP LLC (1) 87-3998289 | 558,918 | 10.0% | SCHEDULE 13G ↗ |
| Jan 16, 2025 | SCHEDULE 13G | KZIA Kazia Therapeutics Limited | Alumni Capital LP, 87-3893017 | 558,918 | 10.0% | SCHEDULE 13G ↗ |
32 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 8:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances